NeuralStem
Rockville
About NeuralStem
Neuralstem, Inc. is a publicly traded biotherapeutics company. The company aims to apply "stem cell research and its patented human neural stem cell technology to treat diseases of the central nervous system including Ischemic Paraplegia, Traumatic Spinal Cord Injury, ALS and Parkinson’s Disease." Neuralstem's research has allowed them to produce mature, commercial quantities of neural stem cells that can be transplanted into humans as treatments for currently incurable diseases.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $39.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jul 2019)
- Ticker: nasdaq:SNCA
- Website: neuralstem.com
- Phone: +30136649606
Industries & Categories
Biotechnology, Health Care, Neuroscience, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/neuralstem-188445 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.